Clinical and laboratory findings from patients with COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study

Abstract

Background. In December, 2019, China, has experienced an outbreak of novel coronavirus disease 2019 . Coronavirus has now spread to all of the continents. We aimed to consider clinical characteristics, laboratory data of COVID-19 that provided more information for the research of this novel virus. Methods.We performed a retrospective cohort study on the clinical symptoms and laboratory findings of a series of the 100 confirmed patients with COVID-19. These patients were admitted to the hospitals affiliated to Babol University of Medical Sciences (Ayatollah Rohani, ShahidBeheshti and Yahyanejad hospitals) form 25 February 2020 to 12 March 2020. Results.Nineteen patients died during hospitalization and 81 were discharged. Non-survivor patients had a significantly higher C-reactive protein (CRP) (MD: 46.37, 95% CI: 20.84, 71.90; P= 0.001), white blood cells (WBCs) (MD: 3.10, 95% CI: 1.53, 4.67; P< 0.001) and lower lymphocyte (MD: -8.75, 95% CI: -12.62, -4.87; P< 0.001) compared to survivor patients Data analysis showed that comorbid conditions (aRR: 2.99, 95%CI: 1.09, 8.21, P= 0.034), higher CRP levels (aRR: 1.02, 95%CI: 1.01, 1.03, P= 0.044), and lower lymphocyte (aRR: 0.82, 95%CI: 0.73, 0.93, P= 0.003) were associated with increased risk of death. Conclusions.Based on our findings, most non-survivors are elderly with comorbidities. Lymphopenia and increased levels of WBCs along with elevated CRP were associated with increased risk of death. Therefore, it is best to be regularly assessed these markers during treatment of COVID-19 patients.

Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis

“…Amongst these 37 articles, 26 articles (25 original studies and 1 narrative review) reported mortality in COVID-19 patients with ARDS (with or without corticosteroid use) and were selected for further quantitative analysis [ 31 – 36 , 39 – 41 , 43 – 46 , 48 – 50 , 52 – 56 , 58 – 62 ]. In addition, we also retrieved two national reports, one each from France [ 68 ] and Spain [ 69 ] that were also included in the quantitative synthesis of mortality in COVID-19 associated ARDS.…”

“…The Newcastle–Ottawa scale was applied for the quality assessment (supplementary data, Table S1) of studies included in the quantitative synthesis of mortality in COVID-19 patients with ARDS. Of the 25 original studies included in the meta-analysis, 16 studies were deemed ‘good’ studies with a score of seven points [ 31 , 33 – 35 , 40 , 41 , 44 – 46 , 49 , 50 , 52 , 53 , 56 , 58 , 60 ] ( Table 1 ). Whereas the remaining 9 studies were regarded as ‘fair’ with a score of 6 points [ 32 , 36 , 39 , 43 , 48 , 54 , 59 , 61 , 62 ] ( Table 1 ).…”

“…31- 36,39-41,43-46,48-50,52-56,58-62], including 19 studies (76%)[31][32][33][34][35][36][39][40][41][43][44][45][46][48][49][50][52][53][54] from China, of which 16 studies (64%)[31][32][33][34][35][36][39][40][41][44][45][46]49,50,52,53] were conducted in the Wuhan city. The remaining 6 studies were from Italy (n = 3)[58][59][60], Germany (n = 1)[61], Poland (n = 1)[62], and Iran (n = 1)[56]. In addition, only 10 out of the 25 original studies are multicenter[34,35,41,[44][45][46]48,49,…”

“…Germany was found to have the lowest mortality estimate among COVID-19 patients with ARDS (13%; 95% CI: 2-29%). Subgroup analysis which limited only to the studies from Asia (China and Iran) involving COVID-19 patients with ARDS[31][32][33][34][35][36][39][40][41][43][44][45][46][48][49][50][52][53][54][55][56] presented a mortality estimate of 65% (95% CI: 53-76%). Subgroup analysis which limited only to the studies/reports involving COVID-19 patients with ARDS from European countries[58][59][60][61][62] reported a mortality estimate of 34% (95% CI: 20-50%).…”

Clinical presentation and outcomes of hospitalized adults with COVID‐19: A systematic review

“…(Deng, Hu, et al, 2020; Inciardi et al., 2020; Shi, Qin, et al, 2020; Wang, Lu, et al, 2020; Yang et al., 2020a; Zhao, Xu, et al, 2020). Secondary infections (30%) and septic shock (32%) are common among severe COVID‐19 patients (Javanian et al., 2020; Tang et al., 2020). In one cohort, 97% of patients requiring invasive mechanical ventilation and 50% of patients with secondary infections died (Zhou, Yu, et al, 2020).…”